Search
Clinician Ordering Portal
Scientific Evidence
Clinical use of a diagnostic gene expression signature for melanocytic neoplasms
May 2021
Patients managed in accordance with a benign 23-GEP result, including forgoing re-excision, reported no adverse events during the follow-up period.
Publication: Cutis
Clinical validity of a gene expression signature in diagnostically uncertain neoplasms
Jun 2020
A retrospective study demonstrating high diagnostic accuracy of the 23-GEP in diagnostically uncertain cases when evaluated against clinical outcomes.
Publication: Personalized Medicine
Correlation of melanoma gene expression score with clinical outcomes on a series of melanocytic lesions
Apr 2019
Clinical validation study of the 23-GEP in lesions with clinical outcomes and follow-up data.
Publication: Human Pathology
Gene expression signature as an ancillary method in the diagnosis of desmoplastic melanoma
Dec 2017
Assessment of the sensitivity and specificity of 23-GEP in melanocytic lesions with a desmoplastic component.
Publication: Human Pathology
Diagnostic distinction of malignant melanoma and benign nevi by a gene expression signature and correlation to clinical outcomes
Jul 2017
Large outcomes-proven validation cohort establishes high levels of sensitivity and specificity in melanomas with proven distant metastasis and nevi with 6+ years of event free follow-up.
Publication: Cancer Epidemiology, Biomarkers, and Prevention
The influence of a gene expression signature on the treatment of diagnostically challenging melanocytic lesions
Jan 2017
MyPath Melanoma guides dermatologists in treatment decisions leading to a 72% reduction in re-excisions when the GEP result is benign.
Publication: Personalized Medicine
An independent validation of a gene expression signature to differentiate malignant melanoma from benign melanocytic nevi
Oct 2016
Establishes the performance of the gene expression signature in prospectively submitted cases with triple concordant diagnosis.
Publication: Cancer
The influence of a gene expression signature on the diagnosis and recommended treatment of melanocytic tumors by dermatopathologists
Oct 2016
Definitive diagnoses by dermatopathologists in challenging melanocytic lesions increased by 57% by incorporating the results of 23-GEP.
Publication: Medicine
Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma
Mar 2015
Initial development and validation of the 23-GEP establishing a high level of sensitivity and specificity in a broad range of histopathological subtypes.
Publication: Journal of Cutaneous Pathology
Analytical validation of a melanoma diagnostic gene signature using formalin-fixed paraffin-embedded melanocytic lesions
Mar 2015
Analytical validation study to establish precision, dynamic range, RNA yield, reproducibility, and melanin inhibition.
Publication: Biomarkers in Medicine